These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 14769687)

  • 21. Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
    Steinhubl SR
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S12-9. PubMed ID: 17224886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization.
    Lenzen MJ; Boersma E; Bertrand ME; Maier W; Moris C; Piscione F; Sechtem U; Stahle E; Widimsky P; de Jaegere P; Scholte op Reimer WJ; Mercado N; Wijns W;
    Eur Heart J; 2005 Jun; 26(12):1169-79. PubMed ID: 15802360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
    Moser LR; Kalus JS
    Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.
    Hoekstra JW; Roe MT; Peterson ED; Menon V; Mulgund J; Pollack CV; Miller C; Palabrica T; Harrington RA; Ohman EM; Gibler WB
    Acad Emerg Med; 2005 May; 12(5):431-8. PubMed ID: 15863399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Tricoci P; Newby LK
    Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
    Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Myocardial revascularization in acute coronary syndrome without ST-segment elevation].
    Hamon M
    Rev Prat; 2003 Mar; 53(6):629-34. PubMed ID: 12749149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
    Galli M; Vassanelli C
    Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
    [No Abstract]   [Full Text] [Related]  

  • 31. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Maree A; Fitzgerald D
    Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Harding SA; Boon NA; Flapan AD
    Lancet; 2002 Jul; 360(9328):256-7. PubMed ID: 12133681
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute coronary syndromes: optimizing the therapeutic options.
    Gershlick AH
    Eur Heart J; 2002 Feb; 23(3):194-7. PubMed ID: 11792132
    [No Abstract]   [Full Text] [Related]  

  • 34. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 35. NICE appraisals and cardiology: glycoprotein IIb/IIIa inhibitors and acute coronary syndromes.
    Hyde T; Knight C
    Hosp Med; 2003 Nov; 64(11):638-9. PubMed ID: 14671871
    [No Abstract]   [Full Text] [Related]  

  • 36. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Boersma E; Harrington RA; Moliterno DJ; White H; Simoons ML
    Lancet; 2002 Jul; 360(9329):342-3. PubMed ID: 12147403
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of patients with acute coronary syndrome in the United States with glycoprotein IIb/IIIa inhibitors. Data provided by the PURSUIT study].
    Galvani M
    Ital Heart J Suppl; 2000 Dec; 1(12):1650-1. PubMed ID: 11221597
    [No Abstract]   [Full Text] [Related]  

  • 38. Invasive coronary revascularisation is better than conservative treatment in patients with acute coronary syndromes.
    Gonzi G; Merlini PA; Ardissino D
    Heart; 2001 Oct; 86(4):363-4. PubMed ID: 11559667
    [No Abstract]   [Full Text] [Related]  

  • 39. ASSENT-3: implications for future trial design and clinical practice.
    Van de Werf F
    Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute coronary syndrome.
    Khavandi A; Walker PR
    BMJ; 2007 Mar; 334(7595):647-8. PubMed ID: 17395906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.